- Home
- ACRS vs LOCO Comparison
ACRS vs LOCO Comparison
Compare ACRS & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | LOCO |
|---|---|---|
| Founded | 2012 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 456.5M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACRS | LOCO |
|---|---|---|
| Price | $3.94 | $14.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $10.36 | ★ $20.75 |
| AVG Volume (30 Days) | ★ 2.4M | 306.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | 4.65 |
| EPS | N/A | ★ 0.93 |
| Revenue | $1,683,000.00 | ★ $401,701,000.00 |
| Revenue This Year | N/A | $2.70 |
| Revenue Next Year | N/A | $4.35 |
| P/E Ratio | ★ N/A | $15.89 |
| Revenue Growth | N/A | ★ 5.68 |
| 52 Week Low | $2.34 | $9.99 |
| 52 Week High | $6.60 | $17.40 |
Technical Indicators
Market Signals| Indicator | ACRS | LOCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 47.29 |
| Support Level | $3.24 | $14.23 |
| Resistance Level | $4.67 | $15.76 |
| Average True Range (ATR) | 0.30 | 0.63 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 52.08 | 39.54 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.